Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Pfizer Inc.

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer

October 19, 2025

From Pfizer Inc.

Via Business Wire

Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer

October 19, 2025

From Pfizer Inc.

Via Business Wire

TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial

October 14, 2025

From Pfizer Inc.

Via Business Wire

Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025

October 13, 2025

From Pfizer Inc.

Via Business Wire

Pfizer Declares Fourth-Quarter 2025 Dividend

October 09, 2025

From Pfizer Inc.

Via Business Wire

Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients

September 30, 2025

From Pfizer Inc.

Via Business Wire

Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025

September 25, 2025

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts

September 23, 2025

From Pfizer Inc.

Via Business Wire

Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio

September 22, 2025

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

September 08, 2025

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

August 27, 2025

From Pfizer Inc.

Via Business Wire

PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery

August 12, 2025

From Pfizer Inc.

Via Business Wire

Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance

August 05, 2025

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union

July 25, 2025

From Pfizer Inc.

Via Business Wire

Pfizer Completes Licensing Agreement with 3SBio

July 24, 2025

From Pfizer Inc.

Via Business Wire

XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

July 10, 2025

From Pfizer Inc.

Via Business Wire

Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors

June 26, 2025

From Pfizer Inc.

Via Business Wire

Pfizer Declares Third-Quarter 2025 Dividend

June 25, 2025

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts

June 25, 2025

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

June 02, 2025

From Pfizer Inc.

Via Business Wire

Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

May 30, 2025

From Pfizer Inc.

Via Business Wire

Pfizer Enters into Exclusive Licensing Agreement with 3SBio

May 19, 2025

From Pfizer Inc.

Via Business Wire

Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance

April 29, 2025

From Pfizer Inc.

Via Business Wire

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

April 26, 2025

From Pfizer Inc.

Via Business Wire

Pfizer Declares Second-Quarter 2025 Dividend

April 23, 2025

From Pfizer Inc.

Via Business Wire

Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting

April 23, 2025

From Pfizer Inc.

Via Business Wire

ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease

April 16, 2025

From Pfizer Inc.

Via Business Wire

Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron

April 14, 2025

From Pfizer Inc.

Via Business Wire

Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24

April 10, 2025

From Pfizer Inc.

Via Business Wire

European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease

April 01, 2025

From Pfizer Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.